News

Financial details have not been disclosed. Proleukin® is licensed in around 20 countries around the world and is primarily indicated for use in metastatic renal cell carcinoma, as

Baloxavir marboxil was discovered by Shionogi & Co. and is being developed globally by the Roche Group (which includes Genentech in the US) and Shionogi & Co. The drug

TPOXX is claimed to be the first drug with an indication for treatment of smallpox, which is a contagious and fatal infectious disease. The approval of small-molecule antiviral

The partnership will engage in the discovery and development of next-generation bispecific immunotherapies for multiple cancer indications. Under the deal, Immatics will secure an upfront fee of $54m

As of August 2018, a new Logistics Hub in Santiago de Chile will benefit the growing pharma & healthcare industry in South America with a dedicated warehousing solution.

Visterra is engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Otsuka Pharmaceutical representative director and president

Idera said that majority of its stockholders voted in favor of the adoption of the merger agreement with BioCryst. BioCryst will pay $6m as transaction-related expenses to Idera,

As per the cash-cum stock deal signed in early May, the Japanese pharma company offers to pay $30.33 in cash for each Shire share in addition to either

The agency said that the recall pertains to medicines which use valsartan supplied by China-based Zhejiang Huahai Pharmaceuticals. It revealed that the review was launched after Zhejiang Huahai